EditorialThe FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
Under an Elsevier user license
open archive
Cited by (0)
© 2020 European Society for Medical Oncology. Published by Elsevier Ltd.